Do Peptides Cause Cancer? The Framework Behind Next Week’s Full Course
Research and educational purposes only. Nothing here is medical advice. All discussion of peptides refers to research compounds — not for human consumption. If you’re navigating a personal diagnosis or risk factor, that’s a conversation for a qualified oncologist, not a Substack post.
ARE THE CLAIMS REAL?
This is the question that lands in every DM, every comment thread, every podcast Q&A. “Do peptides cause cancer?” Or some version of it — “is BPC-157 going to give me a tumor,” “is TB-500 dangerous,” “can IGF-1 trigger something.”
The short answer, and I want to be transparent that this is my read of the literature and not a medical claim: peptides, as a class, do not cause cancer. They contribute to pathways that already exist. That distinction matters more than almost anything else in this space, and most people get it wrong because the headlines and the marketing both have an incentive to flatten it.
What you’re reading is the framework — the 10,000-foot view. Next week I’m dropping the full course inside the Research Radar classroom on Skool: a 17-module walkthrough that takes every pathway named below and breaks it down one at a time, in beginner-accessible language, with the deeper literature linked for anyone who wants to keep going. Module list at the bottom of this post.
For now, here’s the framework.
The core distinction: initiation vs promotion
Cancer biology splits cleanly into two stages, and confusing them is where most of the fear in this community comes from.
Initiation is when a normal cell becomes a cancer cell. This requires DNA damage — mutations in oncogenes, loss of tumor suppressor function, chromosomal instability. The causes are well-mapped: tobacco smoke, ionizing radiation, certain viruses, specific carcinogens, inherited mutations like BRCA, chronic inflammation over long timelines. None of the peptides discussed in this community are mutagens. None of them damage DNA. None of them transform normal cells into cancer cells in any model that has been published.
Promotion is what happens after a cancer cell already exists. Tumors need blood supply, growth signals, the ability to migrate, and resistance to programmed cell death. Anything that supplies those inputs can theoretically accelerate a tumor that is already there. This is where peptides sit. The growth-signaling peptides this community uses — BPC-157, TB-500, IGF-1 LR3, GHK-Cu in some contexts — modulate the exact pathways tumors hijack for their own purposes.
That is the entire conversation in one sentence: peptides don’t start the fire, but several of them can be fuel if a fire is already burning.
BPC-157 and the VEGF/VEGFR2 angiogenic pathway
BPC-157 is one of the most well-studied peptides in the regenerative space, and its core mechanism is angiogenesis — the formation of new blood vessels.
The published mechanism is clear. BPC-157 upregulates VEGF (vascular endothelial growth factor) expression, increases VEGFR2 (the receptor that responds to VEGF), and activates the VEGFR2-Akt-eNOS signaling cascade. This is what drives the wound healing, the tendon repair, the gut lining regeneration that researchers have observed across dozens of preclinical models.
The cancer-relevant context: VEGF/VEGFR2 signaling is hijacked by roughly half of all solid tumors as the mechanism by which they recruit their own blood supply. Anti-angiogenic drugs like bevacizumab exist specifically to block this pathway in cancer patients. So a peptide that upregulates VEGFR2 is operating on the same machinery that aggressive tumors depend on.
Important nuance: in isolated human melanoma cell lines, BPC-157 has actually been shown to inhibit VEGF signaling via the MAPK kinase pathway. In murine models of C26 colon adenocarcinoma, researchers administering BPC-157 observed reduced cachexia, preserved muscle mass, and prolonged survival — without accelerated tumor growth. The picture is not “BPC-157 grows tumors.” The picture is “BPC-157 modulates angiogenic signaling, and in a body with no existing malignancy, that signaling drives healing.”
TB-500 (thymosin beta-4) and the migration/EMT machinery
TB-500 is the synthetic fragment of thymosin beta-4, a 43-amino-acid peptide that exists in nearly every cell in the human body. Its functions are foundational: actin sequestration, cell migration, angiogenesis, anti-inflammatory signaling, tissue remodeling.
Here is what the oncology literature actually shows. Endogenous thymosin beta-4 is elevated in melanoma, colorectal cancer, non-small-cell lung cancer, hepatocellular carcinoma, and several others. In hepatoblastoma research, TB4 has been shown to drive epithelial-mesenchymal transition (EMT) — the cellular switch that lets a tumor cell stop behaving like settled tissue and start behaving like a migratory invader. EMT is one of the central mechanisms of metastasis.
The mechanistic read, which is the part most people miss: TB4 is a marker of aggressive tumors, but the published evidence does not show TB4 transforming normal cells into cancer cells. Cancer cells upregulate it because they need its migration and angiogenic properties. There is no human study demonstrating that researchers administering exogenous TB-500 caused cancer to develop in a healthy subject.
But the pathway overlap is real, and it is the reason any honest discussion of TB-500 in this community has to acknowledge: if a malignancy is already present, this is not a peptide you want introducing more migratory and angiogenic signaling into the environment.
IGF-1 LR3 and the PI3K/Akt/mTOR axis
This is the one that should get the most attention, and it gets the least.
IGF-1 LR3 binds the IGF-1 receptor (IGF1R) and activates two pathways simultaneously: PI3K/Akt/mTOR (which drives protein synthesis, anti-apoptotic signaling, and cellular survival) and MAPK/ERK (which drives cell proliferation). In a muscle cell, this is hypertrophy and satellite cell activation. In a tumor cell, this is the engine of progression.
The oncology evidence here is not theoretical. IGF1R is overexpressed in breast, prostate, colorectal, lung, and renal cancers. In clear cell renal cell carcinoma, IGF1R overexpression is associated with roughly a 70 percent increased risk of death compared to tumors without IGF1R expression. Epidemiological studies link chronically elevated circulating IGF-1 to higher risk of colorectal, breast, and prostate cancer. Multiple pharma programs have spent the last fifteen years developing IGF1R inhibitors specifically as anti-cancer agents.
The takeaway for a beginner: IGF-1 LR3 is the peptide where the cancer-pathway overlap is most direct and most documented. The same signaling that builds muscle is the signaling that resists apoptosis in tumor cells. This is why anyone with a personal or family history of hormone-sensitive cancers needs to think very seriously before going near this compound, even in a research context.
GHK-Cu and the interesting reverse case
GHK-Cu is where the story gets genuinely interesting and where I want to be careful about painting all “growth-signaling” peptides with one brush.
GHK-Cu is a copper-binding tripeptide, and the published gene expression work on it shows a pattern that does not match the rest of this list. In MCF7 breast cancer cells and PC3 prostate cancer cells, GHK has been shown to upregulate multiple tumor suppressor genes — PTEN, BRCA1, CDKN1C, ING4 — while downregulating gene programs associated with cancer enhancement. It stimulates USP29, which stabilizes p53. It increases expression of p73, a member of the p53 family. It has been shown to reverse roughly 70 percent of the pathological gene expression in a published metastasis-prone colon cancer signature.
This does not make GHK-Cu an anti-cancer agent. The data is preclinical and gene-expression-level, not clinical outcome data. But it is a useful corrective to the assumption that anything in the “regenerative peptide” category must by default be tumor-promoting. The mechanism matters. A peptide that upregulates p53 and PTEN is doing something fundamentally different than a peptide that activates IGF1R.
The grounded take
Here is where I land on this, and again, this is my read — not a medical claim.
Peptides do not cause cancer. They do not damage DNA, they do not initiate malignant transformation, and there is no published human study showing that any of the peptides this community discusses turned a healthy subject into a cancer patient.
What peptides do is operate on pathways. Some of those pathways — VEGF, IGF1R, mTOR, EMT machinery — happen to be the same pathways tumors use. In a healthy body with no existing malignancy, this is regeneration. In a body with an undetected tumor, the same signaling could plausibly accelerate progression.
The practical implications follow directly. Anyone with a personal or family cancer history should be far more cautious. Anyone over a certain age should consider that subclinical neoplastic processes are statistically more likely. Anyone using growth-signaling peptides chronically, without washouts, without baseline screening, without paying attention to family history, is taking on risk they may not be quantifying correctly.
This is also why I am so consistent about washout periods. Four to six weeks off, minimum, between cycles. Not because peptides cause cancer, but because chronic uninterrupted growth signaling is a poor strategy regardless of which specific compound is delivering it.
The full course drops next week in the Research Radar classroom
This Substack post is the framework. Next week the full course goes live inside the Skool classroom — 17 modules, each one walking through a single pathway or peptide in beginner-accessible depth, with the literature linked for anyone who wants to keep going. The classroom format means you can work through it at your own pace and come back to specific modules when a question comes up.
Here is the module breakdown that’s dropping:
Module 1 — Cancer initiation vs promotion: the foundational biology
Module 2 — VEGF, VEGFR2, and the angiogenic switch
Module 3 — PI3K/Akt/mTOR: the master growth axis
Module 4 — MAPK/ERK and proliferative signaling
Module 5 — IGF-1R signaling and the IGF/insulin overlap
Module 6 — Epithelial-mesenchymal transition and metastasis
Module 7 — Apoptosis resistance and the anti-apoptotic peptide problem
Module 8 — Tumor suppressor pathways: p53, PTEN, BRCA1
Module 9 — BPC-157 deep dive: angiogenesis in healing vs disease
Module 10 — TB-500 deep dive: migration, EMT, and the TB4 oncology literature
Module 11 — IGF-1 LR3 deep dive: the most documented overlap
Module 12 — GHK-Cu deep dive: the tumor suppressor pattern
Module 13 — Growth hormone secretagogues and the IGF-1 question
Module 14 — Tesamorelin, CJC, Ipamorelin: pulsatile vs sustained signaling
Module 15 — Risk stratification: family history, age, baseline screening
Module 16 — Washout strategy and pathway recovery
Module 17 — The future: peptides being studied as cancer adjuncts
If you’re already inside the Research Radar Skool community, you’ll get a notification when it goes live. If you’re not in yet, this is the kind of course that’s worth being there for — and I’ll post the direct link here when it ships.
Partial reference list
Hsieh et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. (PubMed 27847966)
Kang et al. BPC 157 counteracts tumor cachexia in C26 colon adenocarcinoma model.
Goldstein, Hannappel, Kleinman. Thymosin beta-4: actin sequestering protein moonlights to repair injured tissues.
Cha, Jeong, Kleinman. Role of Thymosin beta-4 in tumor metastasis and angiogenesis. JNCI 2003.
Pollak. The insulin and insulin-like growth factor receptor family in neoplasia. Nat Rev Cancer 2008.
Pickart, Vasquez-Soltero, Margolina. GHK and the human skin remodeling peptide — anti-cancer gene expression patterns. Multiple papers, 2014–2018.
Pickart et al. Modulation of gene expression in human breast cancer MCF7 and prostate cancer PC3 cells by GHK-Cu. OBM Genetics 2021.
Full reference list, with PubMed links and module-by-module breakdowns, will be inside the classroom course.
All compounds discussed are for research and educational purposes only. Not for human consumption. Nothing in this post constitutes medical advice. Anyone considering peptides personally — especially with any cancer history or risk factor — needs to have that conversation with a qualified clinician.
How do you get into the group?
Outstanding post Yet again you knock it out of the ballpark. Looking forward to the guide in Skool.
Thank you Derek! (and please do not forget to apply sunscreen while taking those gorgeous ocean walks)